Anti-SV2A antibody [15E11]
| Name | Anti-SV2A antibody [15E11] |
|---|---|
| Supplier | Abcam |
| Catalog | ab49572 |
| Prices | $391.00 |
| Sizes | 100 µl |
| Host | Mouse |
| Clonality | Monoclonal |
| Isotype | IgG1 |
| Clone | 15E11 |
| Applications | WB IP ICC/IF ICC/IF IHC-P FC |
| Species Reactivities | Rat, Human |
| Antigen | Prokaryotic recombinant protein corresponding to the N-terminal cytoplasmic domain of the human synaptic vesicle 2A molecule |
| Description | Mouse Monoclonal |
| Gene | SV2A |
| Conjugate | Unconjugated |
| Supplier Page | Shop |
Product images
SV2A was immunoprecipitated using 0.5mg Rat Brain tissue lysate, 5µg of Mouse monoclonal to and 50µl of protein G magnetic beads (+). No antibody was added to the control (-).The antibody was incubated under agitation with Protein G beads for 10min, Rat Brain tissue lysate lysate diluted in RIPA buffer was added to each sample and incubated for a further 10min under agitation.Proteins were eluted by addition of 40µl SDS loading buffer and incubated for 10min at 70°C; 10µl of each sample was separated on a SDS PAGE gel, transferred to a nitrocellulose membrane, blocked with 5% BSA and probed with ab49572.Secondary: Goat polyclonal to mouse IgG light chain specific (HRP) at 1/20,000 dilution.Band: 83kDa; SV2A
Human cerebellum: immunohistochemical staining for SV2A using 1/50 ab49572. Note staining of neuronal processes. Paraffin section.
![Overlay histogram showing SH-SY5Y cells stained with ab49572 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab49572, 1/50 dilution) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed.](http://www.bioprodhub.com/system/product_images/ab_products/2/sub_5/7203_SV2A-Primary-antibodies-ab49572-1.jpg)
Overlay histogram showing SH-SY5Y cells stained with ab49572 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab49572, 1/50 dilution) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed.
Product References
Antiepileptic effects of levetiracetam in a rodent neonatal seizure model. - Antiepileptic effects of levetiracetam in a rodent neonatal seizure model.
Talos DM, Chang M, Kosaras B, Fitzgerald E, Murphy A, Folkerth RD, Jensen FE. Pediatr Res. 2013 Jan;73(1):24-30.
Synaptic vesicle protein 2A predicts response to levetiracetam in patients with - Synaptic vesicle protein 2A predicts response to levetiracetam in patients with
de Groot M, Aronica E, Heimans JJ, Reijneveld JC. Neurology. 2011 Aug 9;77(6):532-9.
Neuronal PINCH is regulated by TNF-alpha and is required for neurite extension. - Neuronal PINCH is regulated by TNF-alpha and is required for neurite extension.
Jatiani A, Pannizzo P, Gualco E, Del-Valle L, Langford D. J Neuroimmune Pharmacol. 2011 Sep;6(3):330-40.
Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and - Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and
de Groot M, Toering ST, Boer K, Spliet WG, Heimans JJ, Aronica E, Reijneveld JC. Neuro Oncol. 2010 Mar;12(3):265-73.
Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia - Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia
Toering ST, Boer K, de Groot M, Troost D, Heimans JJ, Spliet WG, van Rijen PC, Jansen FE, Gorter JA, Reijneveld JC, Aronica E. Epilepsia. 2009 Jun;50(6):1409-18.